| Condition | Agent | Class / mechanism | Evidence summary | Trials | Literature | Links |
|---|---|---|---|---|---|---|
| Loading index… | ||||||
How the evidence score works
The score is computed at build time from the fields that already exist in the OSMF data. It is additive and fully reproducible from the pair pages:
Source code: scripts/lib/repurposing_data.py (score), scripts/build_repurposing_index.py (this index) and scripts/build_pair_pages.py (pair pages).
Frequently asked questions
What is the Drug Repurposing Explorer?
A research map that lists, for each condition tracked by the Open Source Medicine Foundation, the candidate drugs, supplements, devices and behavioural interventions that have at least one registered clinical trial or published literature item linked to that condition. Candidates are ranked by a transparent evidence score. It is not treatment advice.
How is the evidence score calculated?
Each registered trial scores by status (recruiting, active or enrolling 3; completed 2.5; not yet recruiting 2; unknown 1; terminated, withdrawn or suspended 0.5) plus a phase bonus (phase 3-4 add 2, phase 2 adds 1, phase 1 adds 0.5), capped at 30. Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other 1), capped at 30. The existing evidence tier adds 15 for A, 10 for B, 5 for C and 0 for D. Agents approved for any indication add 5. The score ranks how much a pair has been studied, not whether it works.
Where does the data come from?
ClinicalTrials.gov registry entries, PubMed literature searches, Open Targets, ChEMBL and DGIdb drug-disease associations, and the OSMF therapeutic agent database for post-viral conditions such as Long COVID, ME/CFS, POTS and MCAS. Links on every row lead to the primary records.
Can I use this to choose a treatment?
No. The explorer summarises what has been studied, not what works or is safe for a given person. Many listed agents are investigational, used off-label, or have only preliminary evidence. Discuss any treatment decision with a qualified clinician.